South Korean Financial Regulator Accused Samsung BioLogics of Accounting Violations

Friday, November 16, 2018 Print Email

South Korea’s financial regulator has said that Samsung BioLogics has violated accounting rules with regards to the treatment it has adopted to account for its holdings in one of its subsidiary. The company in question is known for manufacturing drugs as well as being known as part of the Samsung group.

The Securities and Futures Commission (SFC) has said that Samsung BioLogics violated accounting rules just before its listing as the company changed the treatment it used for accounting its holdings in one of its subsidiary with the name of Samsung Bioepis in the year 2015. The company has denied all the allegations from SFC.

The financial regulator has released a statement as per which it has not only recommended to dismiss the chief executive of the company but also to impose penalty of ₩8bn (£5.5m). SFC is also planning to refer the case to prosecutors. 

It is expected that trading of the stocks of Samsung BioLogistics will temporarily be suspended by the Korean stock exchange until a decision is made regarding whether the company is it reviews whether the company is eligible to remain listed on the Korean stock exchange.  

It is expected that samjong KPMG, the company’s auditor, will be banned from performing the audit of the company for the next 5 years for its negligence and not performing its duties with due care while Deloitte Anjin will be banned from performing the audit of Samsung BioLogics for the next 3 years for its negligence. 

The company has said that they would like to apologize to our shareholders and clients for the confusion and chaos that is being created due to the recent accounting scandal. The company further said that announcement from the SFC is pretty unfortunate as it is our belief that Samsung BioLogics has not violated any accounting rules.

The company did a due diligence from the Korean Institute of Certified Public Accountants (KICPA) which concluded that the accounting treatment of the holdings was appropriate and in addition to this the company also received an official response from the Financial Supervisory Service (FSS) as well as opinion from various accounting and consultancy firms that the accounting treatment was appropriate and the correct one.

The company is planning to file a lawsuit to prove that the accounting treatment adopted by the Samsung BioLogics is appropriate and SFC is wrong in this matter.
Source: ReadyRatios

Login to ReadyRatios


Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: